Similar outcome of elderly patients in Intergroup Trial 0096

Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma

Alan R. Yuen, Guangyong Zou, Andrew T. Turrisi, William Sause, Ritsuko Komaki, Henry Wagner Jr., Seena C. Aisner, Robert B. Livingston, Ronald Blum, David H. Johnson

Research output: Contribution to journalArticle

111 Citations (Scopus)

Abstract

BACKGROUND. Elderly patients comprise a significant portion of patients with limited stage small cell lung carcinoma. However, the prognostic importance of age has been controversial, and concern for toxicity often hinders enthusiasm for offering full dose therapy. METHODS. In this retrospective analysis of Intergroup Trial 0096, the authors compared the outcome of patients 70 years or older to those younger than 70 years. Patients received cisplatin 60 mg/m2, Day 1 and etoposide 120 mg/m2, Days 1-3 for 4 cycles and either once or twice daily concurrent thoracic radiotherapy to 45 grays. RESULTS. Of 381 patients, 50 (13%) were age 70 years or older. The elderly group did not differ significantly from those younger than 70 years with respect to gender distribution, performance status, or weight loss. Severe hematologic toxicity (Grade 4-5: 61% vs. 84%; P < 0.01) and fatal toxicity (1% vs. 10%; P = 0.01) occurred more often among older patients. There were no differences in the frequency of nonhematologic toxicities. Response rate (88% vs. 80%; P = 0.11), event free survival rate (5 year, 19% vs. 16%; P = 0.18), time to local failure, and duration of response did not differ between groups. Overall survival rates (5 year, 22% vs. 16%; P = 0.05) favored those younger than 70 years. Much of the difference in overall survival rates between age groups occurred within the first 6 months on study. CONCLUSIONS. Elderly patients had similar response and survival rates compared with those younger than 70 years. However, toxicity, particularly hematologic, was greater among the elderly. Selected older patients, such as those with a good performance status, should be considered for optimum treatment approaches. (C) 2000 American Cancer Society.

Original languageEnglish (US)
Pages (from-to)1953-1960
Number of pages8
JournalCancer
Volume89
Issue number9
DOIs
StatePublished - Nov 1 2000

Fingerprint

Small Cell Lung Carcinoma
Etoposide
Cisplatin
Radiotherapy
Thorax
Survival Rate
Disease-Free Survival
Weight Loss
Age Groups
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Yuen, Alan R. ; Zou, Guangyong ; Turrisi, Andrew T. ; Sause, William ; Komaki, Ritsuko ; Wagner Jr., Henry ; Aisner, Seena C. ; Livingston, Robert B. ; Blum, Ronald ; Johnson, David H. / Similar outcome of elderly patients in Intergroup Trial 0096 : Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. In: Cancer. 2000 ; Vol. 89, No. 9. pp. 1953-1960.
@article{836e9a8c45c548d9a144c7edc36498fe,
title = "Similar outcome of elderly patients in Intergroup Trial 0096: Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma",
abstract = "BACKGROUND. Elderly patients comprise a significant portion of patients with limited stage small cell lung carcinoma. However, the prognostic importance of age has been controversial, and concern for toxicity often hinders enthusiasm for offering full dose therapy. METHODS. In this retrospective analysis of Intergroup Trial 0096, the authors compared the outcome of patients 70 years or older to those younger than 70 years. Patients received cisplatin 60 mg/m2, Day 1 and etoposide 120 mg/m2, Days 1-3 for 4 cycles and either once or twice daily concurrent thoracic radiotherapy to 45 grays. RESULTS. Of 381 patients, 50 (13{\%}) were age 70 years or older. The elderly group did not differ significantly from those younger than 70 years with respect to gender distribution, performance status, or weight loss. Severe hematologic toxicity (Grade 4-5: 61{\%} vs. 84{\%}; P < 0.01) and fatal toxicity (1{\%} vs. 10{\%}; P = 0.01) occurred more often among older patients. There were no differences in the frequency of nonhematologic toxicities. Response rate (88{\%} vs. 80{\%}; P = 0.11), event free survival rate (5 year, 19{\%} vs. 16{\%}; P = 0.18), time to local failure, and duration of response did not differ between groups. Overall survival rates (5 year, 22{\%} vs. 16{\%}; P = 0.05) favored those younger than 70 years. Much of the difference in overall survival rates between age groups occurred within the first 6 months on study. CONCLUSIONS. Elderly patients had similar response and survival rates compared with those younger than 70 years. However, toxicity, particularly hematologic, was greater among the elderly. Selected older patients, such as those with a good performance status, should be considered for optimum treatment approaches. (C) 2000 American Cancer Society.",
author = "Yuen, {Alan R.} and Guangyong Zou and Turrisi, {Andrew T.} and William Sause and Ritsuko Komaki and {Wagner Jr.}, Henry and Aisner, {Seena C.} and Livingston, {Robert B.} and Ronald Blum and Johnson, {David H.}",
year = "2000",
month = "11",
day = "1",
doi = "10.1002/1097-0142(20001101)89:9<1953::AID-CNCR11>3.3.CO;2-Y",
language = "English (US)",
volume = "89",
pages = "1953--1960",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

Similar outcome of elderly patients in Intergroup Trial 0096 : Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma. / Yuen, Alan R.; Zou, Guangyong; Turrisi, Andrew T.; Sause, William; Komaki, Ritsuko; Wagner Jr., Henry; Aisner, Seena C.; Livingston, Robert B.; Blum, Ronald; Johnson, David H.

In: Cancer, Vol. 89, No. 9, 01.11.2000, p. 1953-1960.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Similar outcome of elderly patients in Intergroup Trial 0096

T2 - Cisplatin, etoposide, and thoracic radiotherapy administered once or twice daily in limited stage small cell lung carcinoma

AU - Yuen, Alan R.

AU - Zou, Guangyong

AU - Turrisi, Andrew T.

AU - Sause, William

AU - Komaki, Ritsuko

AU - Wagner Jr., Henry

AU - Aisner, Seena C.

AU - Livingston, Robert B.

AU - Blum, Ronald

AU - Johnson, David H.

PY - 2000/11/1

Y1 - 2000/11/1

N2 - BACKGROUND. Elderly patients comprise a significant portion of patients with limited stage small cell lung carcinoma. However, the prognostic importance of age has been controversial, and concern for toxicity often hinders enthusiasm for offering full dose therapy. METHODS. In this retrospective analysis of Intergroup Trial 0096, the authors compared the outcome of patients 70 years or older to those younger than 70 years. Patients received cisplatin 60 mg/m2, Day 1 and etoposide 120 mg/m2, Days 1-3 for 4 cycles and either once or twice daily concurrent thoracic radiotherapy to 45 grays. RESULTS. Of 381 patients, 50 (13%) were age 70 years or older. The elderly group did not differ significantly from those younger than 70 years with respect to gender distribution, performance status, or weight loss. Severe hematologic toxicity (Grade 4-5: 61% vs. 84%; P < 0.01) and fatal toxicity (1% vs. 10%; P = 0.01) occurred more often among older patients. There were no differences in the frequency of nonhematologic toxicities. Response rate (88% vs. 80%; P = 0.11), event free survival rate (5 year, 19% vs. 16%; P = 0.18), time to local failure, and duration of response did not differ between groups. Overall survival rates (5 year, 22% vs. 16%; P = 0.05) favored those younger than 70 years. Much of the difference in overall survival rates between age groups occurred within the first 6 months on study. CONCLUSIONS. Elderly patients had similar response and survival rates compared with those younger than 70 years. However, toxicity, particularly hematologic, was greater among the elderly. Selected older patients, such as those with a good performance status, should be considered for optimum treatment approaches. (C) 2000 American Cancer Society.

AB - BACKGROUND. Elderly patients comprise a significant portion of patients with limited stage small cell lung carcinoma. However, the prognostic importance of age has been controversial, and concern for toxicity often hinders enthusiasm for offering full dose therapy. METHODS. In this retrospective analysis of Intergroup Trial 0096, the authors compared the outcome of patients 70 years or older to those younger than 70 years. Patients received cisplatin 60 mg/m2, Day 1 and etoposide 120 mg/m2, Days 1-3 for 4 cycles and either once or twice daily concurrent thoracic radiotherapy to 45 grays. RESULTS. Of 381 patients, 50 (13%) were age 70 years or older. The elderly group did not differ significantly from those younger than 70 years with respect to gender distribution, performance status, or weight loss. Severe hematologic toxicity (Grade 4-5: 61% vs. 84%; P < 0.01) and fatal toxicity (1% vs. 10%; P = 0.01) occurred more often among older patients. There were no differences in the frequency of nonhematologic toxicities. Response rate (88% vs. 80%; P = 0.11), event free survival rate (5 year, 19% vs. 16%; P = 0.18), time to local failure, and duration of response did not differ between groups. Overall survival rates (5 year, 22% vs. 16%; P = 0.05) favored those younger than 70 years. Much of the difference in overall survival rates between age groups occurred within the first 6 months on study. CONCLUSIONS. Elderly patients had similar response and survival rates compared with those younger than 70 years. However, toxicity, particularly hematologic, was greater among the elderly. Selected older patients, such as those with a good performance status, should be considered for optimum treatment approaches. (C) 2000 American Cancer Society.

UR - http://www.scopus.com/inward/record.url?scp=0034327927&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034327927&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20001101)89:9<1953::AID-CNCR11>3.3.CO;2-Y

DO - 10.1002/1097-0142(20001101)89:9<1953::AID-CNCR11>3.3.CO;2-Y

M3 - Article

VL - 89

SP - 1953

EP - 1960

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -